First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours

This is a first-in-human Phase I trial testing the safety of a new experimental drug called OATD-02 in people with certain advanced or metastatic solid cancers — specifically colorectal, kidney, or pancreatic cancer, or platinum-resistant ovarian cancer — that have not responded to standard treatments. **You may be eligible if...** - You are 18 or older - You have confirmed advanced or metastatic colorectal, kidney, pancreatic cancer, or recurrent platinum-resistant ovarian cancer - You have tried at least 1 prior standard treatment regimen that did not work - Your general health is good enough to function well (ECOG 0–1) **You may NOT be eligible if...** - You have untreated brain metastases - You have active autoimmune disease or are taking immune-suppressing medications - You have had major surgery or radiation in the last 4 weeks - You have significant heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.